Treatment of Disseminated Sporotrichosis
Clinical Scenario
Disseminated sporotrichosis represents a severe, systemic form of Sporothrix infection in which the disease has spread beyond the initial site of involvement. This presentation warrants a structured, evidence-based antifungal approach distinct from localised forms of the disease.
Treatment Approach — Partial Overview
First-line management involves an initial course of intravenous antifungal therapy, with a transition to an extended oral step-down regimen once the patient has responded. The complete protocol — including agent selection, sequencing criteria, and total treatment duration — is available in full below.
References
DOI: 10.1086/522765
- Amphotericin B, given as a lipid formulation at a dosage of 3–5 mg/kg daily, is recommended for treatment of disseminated sporotrichosis (B-III).
- Amphotericin B deoxycholate, administered at a dosage of 0.7–1.0 mg/kg daily, could also be used but was not preferred by the panel (B-III).
- Itraconazole administered at a dosage of 200 mg twice daily is recommended as step-down therapy after the patient responds to initial treatment with amphotericin B and should be given to complete a total of at least 12 months of therapy (B-III).
View source ↗